Specialty Pharmacy

Company alleges insurers are taking advantage of program to shift cost of Sovaldi.

Within 48 hours of taking the drug, many patients saw decreased potassium levels.

Test distinguishes between HIV-1 antibodies, HIV-2 antibodies, and HIV-1 p24 antigen in human serum or plasma specimens.

PCSK9 inhibitors could cost up to $23.3 billion nationally if widely prescribed.

Joseph Morse, president and chief operating officer of Therigy, LLC, discusses how specialty pharmacies can best utilize data analytics.

Researchers explore potential of sunscreens with cancer-preventive properties.

New process may lead to quicker and more accurate screening processes for drug development.

New procedure seeks to guide therapeutic decisions.

Drug cost mitigated by savings in health care costs on management of conditions that may result from chronic hepatitis C virus.

Study finds less than half of cancer patients have a completed will.

International Academy of Compounding Pharmacists raises several concerns regarding FDA policies.

Many pharmacists are required to work on their feet for long hours, but that can have serious health consequences similar to sitting.

Treating hepatitis C patients who receive health care through Medicaid with Sovaldi could exceed $55 billion.

Amy Grogg, PharmD, senior vice president of Strategy and Commercialization at AmerisourceBergen Specialty Group, discusses methods to improve patient access to specialty medications.

Combination of grazoprevir and elbasvir has been studied in patients with genotype 1 hepatitis C who also have end-stage renal disease and are undergoing regular hemodialysis.

Doxorubicin can be safely omitted in treatments for Wilms' tumor patients deemed least likely to relapse.

Targeting protein that helps cancer cells survive chemotherapy shows promise.

Protein may potentially offer a future therapeutic target.

Takeda plans to target gastrointestinal and oncology medications in the near future.

Stopping smoking extends survival by nearly a year.

Top stories of the week on Specialty Pharmacy Times from July 13 to July 17.

Treatment improves overall survival.

Antibodies critical to stopping spread of viral cells.

T cells derived from lymph nodes expanded and activated in a laboratory before being injected back into patients.

By lowering LDL-C levels, alirocumab may reduce cardiovascular risk.

Study examines history of universal health care in the United States.

Decreased connectivity in network specific regions of brain at the core of cognitive changes.

Shorter duration could reduce the economic impact on health care spending and make treatment more convenient.